HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced it has entered into a Letter of Intent to acquire the assets of a Central American Immunotherapy Company. The acquisition will include a family of immunotherapy products that have been approved for the treatment of patients as an alternative to or as an adjunct therapy before, during and after traditional cancer treatments. HST anticipates completing the pending acquisition of the company at the conclusion of the due diligence period.
This pending acquisition is a part of the evolution of HST’s development of a global presence in the emerging immunotherapy treatment of cancer. The 20 million dollar cash, stock and royalty Agreement will secure the exclusive worldwide rights to ten (10) existing Immunotherapy products. These products have been registered by the respective Government Health Agencies in the CA-4 Nations (Guatemala, Honduras, Nicaragua and El Salvador) and Belize. Additionally, one (1) of the existing products has qualified for registration with the United States Food and Drug Administration (FDA) for use as a prescription based, NDC registered product. The application process has been completed on three (3) additional products. HST expects qualification for registration of these products within the next ninety (90) days. Furthermore, HST expects to make application for FDA registration on an additional two (2) products within the next sixty (60) days.
Ron Howell, President and CEO of HST Global, Inc. stated “HST is excited to have completed the necessary documentation to move forward with this acquisition. These Immunotherapy technologies have been researched, developed and refined over several years, with over 8,000 case studies substantiating the efficacy of the product application. The acquisition of these proven technologies is a major step in the global expansion plans of our wellness centers. We expect the due diligence period to conclude quickly.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.